AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04730674
Drug: tetracycline mixed with xylocaine
RxNorm normalized name: Xylocaine with Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
Trial: NCT00298675
Drug: BSI-201 (iniparib)
RxNorm normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSI-201 administered intravenously (IV), 2x weekly
Trial: NCT01338558
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
Trial: NCT02970097
Drug: 20ml bolus of 0.5% ropivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local anesthetic
Trial: NCT02970097
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50-100 mcg of medication given intravenously before nerve block
Trial: NCT03770013
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: add placebo 9normal saline)
Trial: NCT01633086
Drug: nitric oxide gel
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days
Trial: NCT01633086
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel,BID local use X 28 days
Trial: NCT01163903
Drug: doxorubicin hydrochloride injection
RxNorm normalized name: Doxorubicin Hydrochloride Injection
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
Trial: NCT03549234
Drug: Erector Spinae (single injection)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Trial: NCT03549234
Drug: Paravertebral (single injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Trial: NCT02110446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Trial: NCT02391935
Drug: RCS-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultured, autologous hair follicle cells suspended in cryomedium
Trial: NCT02391935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryomedium
Trial: NCT03687268
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00665990
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
Trial: NCT05245604
Drug: TJO-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
Trial: NCT02047565
Drug: 25 IU/kg Beriplex P/N
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02047565
Drug: 10 IU/kg Beriplex P/N
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02732093
Drug: Na.Cl 0.9% (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02762344
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: routinary heparin administration during coronary angiography/PCI
Trial: NCT02942680
Drug: acetylsalicylic acid started for 24 hours before surgery
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02942680
Drug: acetylsalicylic acid stayed for 5 days before surgery
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00749385
Drug: PN 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
Trial: NCT00749385
Drug: EC naproxen plus EC esomeprazole
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
Trial: NCT00749385
Drug: EC naproxen
RxNorm normalized name: Naproxen 375 MG Oral Tablet, Enteric Coated [EC NAPROXEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated naproxen tablet (500mg)
Trial: NCT00827554
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
Trial: NCT03366220
Drug: Balanced crystalloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
Trial: NCT00553202
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00553202
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01398462
Drug: CWP232291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT01096576
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally twice daily for 5 days
Trial: NCT00003477
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT00358982
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 administered orally three times per wek
Trial: NCT00675194
Drug: Cisplatin, Irinotecan, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01200537
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group of patients will receive estradiol patches prior to the IVF cycle.
Trial: NCT01061437
Drug: PACx14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
Trial: NCT01061437
Drug: PACMx5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
Trial: NCT01061437
Drug: PAx5/PCMx5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
Trial: NCT01478113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
Trial: NCT02318719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02318719
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00073879
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00423293
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
Trial: NCT04492813
Drug: Pharmacokinetic of propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
Trial: NCT02554383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo made to match the study antibiotic given twice a day orally for 10 days
Trial: NCT00157651
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
Trial: NCT02208570
Drug: Volume loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch solution 6ml/kg iv injection
Trial: NCT03900429
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03900429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Tablets
Trial: NCT00370643
Drug: human regular insulin
RxNorm normalized name: Human regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01876615
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental drug
Trial: NCT01876615
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Depain tablet 25mg
Trial: NCT01876615
Drug: YH4808+Diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01390350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg subcutaneous injections on day 0
Trial: NCT03128528
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor.
Trial: NCT02910843
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: • Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
Trial: NCT00691600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo caps or suspension every 12 hours for 10 days
Trial: NCT03376802
Drug: SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT03376802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT01124838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT00249782
Drug: Vehicle control, 2x/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00249782
Drug: ACZONE (dapsone) Gel, 5%, 2x/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00249782
Drug: ACZONE (dapsone) Gel, 5%, 1x/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00249782
Drug: MetroGel® (metronidazole gel), 1.0% 1x/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00249782
Drug: ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01076764
Drug: Placebo (for Otamixaban)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Trial: NCT01076764
Drug: UFH
RxNorm normalized name: Ibrufhalal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Trial: NCT00404885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO BID
Trial: NCT01299116
Drug: Implanon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
Trial: NCT00170404
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01550523
Drug: IGF-1R/AS ODN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
Trial: NCT03082755
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
Trial: NCT01299116
Drug: ParaGard®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Trial: NCT00002463
Drug: MOPP Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
Trial: NCT00002463
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002463
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00130845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00624910
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
Trial: NCT03375580
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg simvastatin, PO qn
Trial: NCT02369861
Drug: Refresh Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application 4 timer per day
Trial: NCT02134119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic dietary supplement
Trial: NCT03232320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Normal saline)
Trial: NCT02019784
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT02355522
Drug: KY jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299116
Drug: Mirena®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
Trial: NCT00002492
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002492
Drug: isolated limb perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01445795
Drug: Placebo QD Fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule QD fasted x7 days
Trial: NCT01445795
Drug: Placebo QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
Trial: NCT01445795
Drug: 100 mg INX-08189 with low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INX-08189 100 mg capsule, with low-fat meal QD for seven days
Trial: NCT01445795
Drug: Placebo with low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule administered with a low-fat meal QD for seven days
Trial: NCT01445795
Drug: Placebo BID Fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID fasted x7 days
Trial: NCT02629003
Drug: [11C]Cimbi-36
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02629003
Drug: [11C]Cimbi-36-5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00770224
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00770224
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04718311
Drug: Oral lichen clinical Healing evaluation
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments were topically applied for 5 days
Trial: NCT01153360
Drug: liothyronine sodium
RxNorm normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
Trial: NCT01153360
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin B12
Trial: NCT01898013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03469349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin placebo-matching intravenous infusion and tablets.
Trial: NCT01393080
Drug: TP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
Trial: NCT03616964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00908349
Drug: Oxcarbazepine XR
RxNorm normalized name: oxcarbazepine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open Label Study
Trial: NCT01699464
Drug: AR-12286 Ophthalmic Solution 0.7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT01699464
Drug: AR-12286 Ophthalmic Solution 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT01951404
Drug: Placebo (for allopurinol)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00241904
Drug: Antiplatelet Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg q day
Trial: NCT02684123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01382498
Drug: Calcium dobesilate (Doxium)
RxNorm normalized name: calcium dobesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg, Tablet, Daily, 3 months
Trial: NCT00241904
Drug: Beta Blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication
Trial: NCT02755701
Drug: Branched-chain Amino Acid
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (livact) will be administered 3 times a day during 24 weeks
Trial: NCT02755701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in the same way
Trial: NCT00241904
Drug: ACE Inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medications, received 1-2 times per day
Trial: NCT01606319
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg every 6 hours as needed
Trial: NCT01606319
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 9.4 mg/kg every 6 hours as needed
Trial: NCT02484664
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
Trial: NCT01601613
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
Trial: NCT01657799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to veliparib capsules for oral administration
Trial: NCT03437941
Drug: CORT125281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing
Trial: NCT03437941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match the appearance of the CORT125281
Trial: NCT02274077
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01705106
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01705106
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01646684
Drug: SOM230
FDA approved: no
EMA approved: no
PMDA approved: no